US21217B1008
US21217B1008
Contineum Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 503.37M EUR | 616.48M EUR | 488.27M EUR | 426.57M EUR |
Enterprise Value | 265.87M EUR | 608.35M EUR | 475.06M EUR | 359.22M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -6.98x | -- | -- | -- |
Price to Sales | -- | -- | -- | -- |
Price to Book | 2.1x | 2.57x | 1.95x | 1.63x |
EV/Revenue | -- | -- | -- | -- |
EV/EBITDA | -4.03x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -6.98% | -8.67% | -11.81% | -9.63% |